1
Jun
2023
Pfizer’s RSV Vaccine OK’d, Coherus Challenges Humira, & Eikon Gets a Pipeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.